what's in glp-1 and Anesthesia: Considerations and Cautions for CRNAs Glucagon-like peptide 1 (GLP-1) -

Tirzepatide is a promising drug withdual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor activation that has revolutionized the treatment of type 2 diabetesmellitus (T2DM) as an adjunct to ...

GLP-1 drugs are reshaping healthcare and consumer markets

Click to learn more about why this may be right for you

February 4, 2026: Washington, DC A year ago, theNational Consumers League took the unusual step offlaggingwarningsfromthe Food and Drug Administration(FDA) and medical societiesstatingthatcompounded versions of GLP-1 (glucagon-like peptide-1 receptor agonists)weight-lossdrugs are not FDA approved and may cause serious health problems.The purposewas toinformconsumers aboutthe potential harm posed by these drugsbeforeHims & Hers, a large telehealth company,aired awidely hyped television ad duringthe 2025 Super Bowl touting only the benefitsof compoundedGLP-1s.

Experts are studying the use of GLP-1 medications to manage rheumatoid arthritis

Should GLP-1 therapy extend to normal-weight patients with cardiometabolic risk